Maciej Banach
Overview
Explore the profile of Maciej Banach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
927
Citations
18149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dyrbus K, Banach M, Gil R, Gasior M, Broncel M, Gellert R, et al.
Kardiol Pol
. 2025 Mar;
PMID: 40066957
Atherosclerosis is a systemic disease and involves not only the coronary vessels but also occurs in other vascular beds (e.g., cervical, cerebral, and peripheral vessels), increasing cardiovascular risk. One of...
2.
Parhofer K, Aguiar C, Banach M, Drexel H, Gouni-Berthold I, de Isla L, et al.
Eur Heart J Cardiovasc Pharmacother
. 2025 Mar;
PMID: 40052330
The clinically important link between low-density lipoprotein cholesterol (LDL-C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines for...
3.
Chen Y, Zhong Z, Gue Y, Banach M, McDowell G, Mikhailidis D, et al.
Lancet Reg Health Eur
. 2025 Mar;
50:101245.
PMID: 40046687
[This corrects the article DOI: 10.1016/j.lanepe.2024.101182.].
4.
Back M, Banach M, Braunschweig F, De Rosa S, Flachskampf F, Kahan T, et al.
Eur Heart J Open
. 2025 Mar;
5(1):oeaf015.
PMID: 40041611
No abstract available.
5.
Giannakodimos A, Oikonomou E, Pantelidis P, Theofilis P, Katsiki N, Goliopoulou A, et al.
Expert Rev Gastroenterol Hepatol
. 2025 Feb;
:1-14.
PMID: 39988816
Introduction: The purpose of this systematic review and meta-analysis is to investigate the association of metabolic dysfunction-associated steatotic liver disease (MASLD) with arterial stiffness and enlighten on potential cardiometabolic co-factors....
6.
Bielecka-Dabrowa A, Trzmielak D, Sakowicz A, Janikowski K, Banach M
Arch Med Sci
. 2025 Feb;
20(6):1797-1808.
PMID: 39967958
Introduction: The aim of this study was to implement a model of healthcare for patients with heart failure (HF) and to assess the differences between men and women in the...
7.
Banach M, Surma S, Dzida G, Jozwiak J, Okopien B, Rysz J, et al.
Arch Med Sci
. 2025 Feb;
20(6):1754-1769.
PMID: 39967951
Cardiovascular diseases (CVD) prevention does not only mean effective fight against the existing and well-recognized cardiovascular risk factors, but also against their complications, including micro- and macrovascular complications. Only then...
8.
Mysliwiec M, Bandura M, Woloszyn-Durkiewicz A, Hennig M, Walczak M, Peregud-Pogorzelski J, et al.
Arch Med Sci
. 2025 Feb;
20(6):1741-1753.
PMID: 39967943
Familial hypercholesterolemia (FH) is the most common monogenic disease leading to the accelerated development of atherosclerotic cardiovascular disease (ASCVD). Despite increasing medical knowledge, diagnostic testing, and a growing number of...
9.
Bytyci I, Bytyqi S, Lewek J, Surma S, Bajraktari G, Henein M, et al.
Eur Heart J Open
. 2025 Feb;
5(1):oeaf001.
PMID: 39944782
Aims: Heterozygous familial hypercholesterolaemia (HeFH) is one of the most frequent monogenic disorders in the world, leading to premature atherosclerotic cardiovascular diseases. The aim of this meta-analysis was to evaluate...
10.
Gryglewska-Wawrzak K, Banach M, Sakowicz A, Sosnowska B, Adach W, Bielecka-Dabrowa A
Cardiol J
. 2025 Feb;
PMID: 39936848
Background: This study aimed to identify factors associated with the 10-year risk of fatal and non-fatal cardiovascular disease (CVD) events in apparently healthy individuals aged 40-69 years. Methods: 148 patients...